A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Gastric01
- Sponsors Daiichi Sankyo Company
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, an interim analysis will occur after all subjects complete tumor assessments on week 18 and when approximately 108 OS events are observed and 12 patients have been enrolled as of 13 Feb 2018.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.